Down 93%, Is It Finally Time to Buy Moderna?
As we near the five-year anniversary of the COVID-19 pandemic, it's a good time to revisit the drugmaker stock that was top of mind back then. A few years ago, Moderna (NASDAQ: MRNA) stock soared on the back of the highly successful vaccine it developed in record time.At its peak in 2021, Moderna traded for over $450 per share. But the good times didn't last. When the market closed on March 11 of this year, the vaccine maker was trading below $34 per share.Is it time to average down on a Moderna holding or begin a new position? Let's look at the company's recent performance and some catalysts that could push the stock higher to see if it deserves a place in your portfolio.Continue reading
As we near the five-year anniversary of the COVID-19 pandemic, it's a good time to revisit the drugmaker stock that was top of mind back then. A few years ago, Moderna (NASDAQ: MRNA) stock soared on the back of the highly successful vaccine it developed in record time.
At its peak in 2021, Moderna traded for over $450 per share. But the good times didn't last. When the market closed on March 11 of this year, the vaccine maker was trading below $34 per share.
Is it time to average down on a Moderna holding or begin a new position? Let's look at the company's recent performance and some catalysts that could push the stock higher to see if it deserves a place in your portfolio.
